BMY Advances CELMoD Program With Positive Phase III Results

Positive phase III SUCCESSOR-2 data show BMY’s mezigdomide combination improved progression-free survival in relapsed multiple myeloma, boosting confidence in the company’s CELMoD program. The readout should meaningfully enhance the therapy’s commercial and regulatory prospects and is likely to move Bristol Myers Squibb shares and sector sentiment.

Analysis

Positive phase III SUCCESSOR-2 data show BMY’s mezigdomide combination improved progression-free survival in relapsed multiple myeloma, boosting confidence in the company’s CELMoD program. The readout should meaningfully enhance the therapy’s commercial and regulatory prospects and is likely to move Bristol Myers Squibb shares and sector sentiment.